Aldeyra achieves primary endpoint in Phase 3 dry eye trial of reproxalap; NDA resubmission planned 2024

Aldeyra Therapeutics, Inc.

Primary endpoint of ocular discomfort met (p=0.004) vs vehicle in 132-patient Phase 3 dry eye chamber trial.
NDA resubmission for reproxalap anticipated in 2024; FDA review period expected ~6 months.
Reproxalap studied in over 2,500 patients; no safety signals; mild transient instillation site discomfort most common AE.
Option agreement with AbbVie includes $100M upfront if exercised, plus up to $300M milestones and profit/loss share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.